Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
American Journal of Psychiatry – January 01, 2025
Source: OpenAlex
Summary
Rapid antidepressant effects are emerging from psychedelics. Unlike classical medicine, hallucinogens like psilocybin and ultra-fast compounds such as 5-MeO-DMT show significant promise in psychiatry. Early pharmacology studies in small samples indicate brief 15-30 minute interventions induce marked improvement in depression symptoms within 24 hours, lasting over a week. These monoamine neurotransmitters primarily act on serotonergic 5-HT receptors, influencing serotonin pathways. This neuroscience, exploring chemical synthesis and how receptors influence behavior, is vital for future psychology and drug studies.
Abstract
Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but brief psychedelic intervention. The current paper reviews the clinical pharmacology of 5-MeO-DMT and DMT and their potential benefits and challenges in the treatment of depression. Both compounds display affinities for a variety of monoamine receptors and transporters, but mostly so for serotonergic (5HT) receptors, including 5HT1A and 5HT2A. Early clinical trials in small samples have shown that short interventions (15-30 min) with 5-MeO-DMT and DMT are safe and well tolerated and can induce marked improvement in symptoms of depression within 24 hours that sustain for at least 1 week. Data on long-term efficacy are currently scarce but do suggest a prolongation of the treatment response. Potential benefits of these treatments include flexible, single day dosing regimens, achievement of treatment efficacy independent from integrative therapy, and ease of clinical implementation. Future challenges include establishing the duration of the antidepressant effect and strategies on how to sustain the antidepressant response, optimization of treatment delivery parameters, and a mechanistic understanding of the clinical response. Acceptance of ultra-fast, short-acting psychedelics will depend on future randomized, placebo-controlled trials with a focus on replication, duration and maintenance of antidepressant efficacy in large patient samples.